News

The Phase 3 study is intended to be a confirmatory study to be completed following the accelerated approval of Marqibo. Talon president and CEO Steven Deitcher said the

Perrigo’s Ketoconazole Foam, 2% is generic equivalent to Extina Ketoconazole Foam, 2%. Ketoconazole Foam, 2% is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years

The company will continue to use the Avantra name for its proteomics portfolio, which includes the Avantra Biomarker System. Courtagen CEO Brian McKernan said the name change reflects

EMD Millipore offers a range of performance products, services and business relationships that enable customers’ success in research, development and production of biotech and pharmaceutical drug therapies. With

NP101 is an active, single-use, transdermal sumatriptan patch being developed for the acute treatment of migraine. The CRL includes chemistry, manufacturing and safety questions, which the company believes

The trial aims to investigate the tolerability and safety of intratumoral injections of ZIN ATI-001 (Ad-RTS-IL-12 or INXN-2001). Mary Crowley Medical Research Center executive medical director John Nemunaitis

Under the agreement, Icon will provide clinical pharmacology and exploratory clinical trial services including study conduct in Icon’s clinical pharmacology units, located in San Antonio, Texas; Omaha, Nebraska;

According to the revised guidelines, ticagrelor is recommended for all non-ST elevation ACS patients at moderate-to-high risk of ischaemic events, regardless of initial treatment strategy and including those

Brahmar Cellulose develops, produces and markets microcrystalline cellulose (MCC) and sodium carboxyl methyl cellulose (SCMC) to the pharmaceutical industry world-wide. The transaction is expected to position DMV-Fonterra Excipients